CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Blood. 2021 Sep 23;138(12):1081-1085. doi: 10.1182/blood.2021010930.

Authors

Vicki Plaks¹, John M Rossi¹, Justin Chou¹, Linghua Wang², Soumya Poddar¹, Guangchun Han², Zixing Wang¹, Shao-Qing Kuang², Fuliang Chu², Richard E Davis², Francisco Vega², Zahid Bashir¹, Caron A Jacobson³, Frederick L Locke⁴, Patrick M Reagan⁵, Scott J Rodig⁶, Lazaros J Lekakis⁷, Ian W Flinn⁸, David B Miklos⁹, Adrian Bot¹, Sattva S Neelapu²

Affiliations

¹ Kite, a Gilead Company, Santa Monica, CA.
² The University of Texas MD Anderson Cancer Center, Houston, TX.
³ Dana-Farber Cancer Institute, Boston, MA.
⁴ Moffitt Cancer Center, Tampa, FL.
⁵ University of Rochester School of Medicine, Rochester, NY.
⁶ Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
⁷ Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL.
⁸ Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; and.
⁹ Stanford University School of Medicine, Stanford, CA.

No abstract available

Publication types

Clinical Trial
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antigens, CD19 / immunology
Biological Products / administration & dosage*
Biological Products / adverse effects
Female
Humans
Lymphoma, Large B-Cell, Diffuse* / diagnostic imaging
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / immunology
Lymphoma, Large B-Cell, Diffuse* / pathology
Male
Middle Aged
Neoplasm Proteins / immunology*
Recurrence
Tumor Escape / drug effects*
Tumor Escape / genetics

Substances

Antigens, CD19
Biological Products
CD19 molecule, human
Neoplasm Proteins
axicabtagene ciloleucel